Friday, October 4, 2019

Congratulations to our own Donna Wiegle!!

It didn't take Donna long to move from an idea of riding cross-country to making it happen during the month of September - ovarian cancer awareness month. Her goal was simple - to talk to anyone and everyone about the signs and symptoms of OC while raising money to support two great causes: Ovations for the Cure of OC and our own Turning-the-Tide Ovarian Cancer Retreats, Inc.

When musing about how much money she should set as her target, she decided go big - $50,000. And she is just shy of that goal. But I'm getting ahead of myself....

For those of us who know Donna, when she sets her mind to something, she makes it happen. When an elderly member of her small community on Swan's Island off the coast of ME was dying, she cooked meals, mowed his lawn, and took care of him.

There was no health care facility on the island, so she started one. It has state-of-the-art telemedicine equipment and here Donna holds classes for the residents, offers blood pressure clinics, arranges for doctors to come to regularly and provide services - in short, she does everything from cleaning the bathroom to drawing blood, saving residents the expense in time and money from leaving the island.

So when the idea of riding a motorcycle cross country and educating men and women about OC, it wasn't a stretch to imagine Donna doing this. She's that kind of woman. When she came across a teal and white Harley for sale one day on the mainland, it didn't take long for the threads of her plan to spin out. She eventually bought the motorcycle, had it specially outfitted for a long journey with the help of her husband Charlie, and the generosity of a local bike shop. She had business cards made up, she received hundreds of cards listing the symptoms of OC from OCRA, got a really cool leather vest inscribed with her logo, "Teal on Wheels", had a flag made up and set her eyes on starting in Oregon for a month long journey.

What has inspired her so much is the generosity of people she has met along her journey - people paying for her meals, handing her $100 bills, even joining in to ride with her along the way. She chronicled her journey on her FB page.

If you haven't yet donated and would like to, you can by following this link to her GoFundMe page.


Thursday, September 26, 2019

Body-on-a-Chip Device Predicts Cancer Drug Responses

Thanks go out to Betsy for sending me this article from the NIH Director's Blog, written by Dr. Francis Collins:

Researchers continue to produce impressive miniature human tissues that resemble the structure of a range of human organs, including the livers, kidneys, hearts, and even the brain. In fact, some researchers are now building on this success to take the next big technological step: placing key components of several miniature organs on a chip at once. 
These body-on-a-chip (BOC) devices place each tissue type in its own pea-sized chamber and connect them via fluid-filled microchannels into living, integrated biological systems on a laboratory plate. In the photo above,(NOT SHOWN), the BOC chip is filled with green fluid to make it easier to see the various chambers. For example, this easy-to-reconfigure system can make it possible to culture liver cells (chamber 1) along with two cancer cell lines (chambers 3, 5) and cardiac function chips (chambers 2, 4). 
Researchers circulate blood-mimicking fluid through the chip, along with chemotherapy drugs. This allows them to test the agents’ potential to fight human cancer cells, while simultaneously gathering evidence for potential adverse effects on tissues placed in the other chambers. 
This BOC comes from a team of NIH-supported researchers, including James Hickman and Christopher McAleer, Hesperos Inc., Orlando, FL. The two were challenged by their Swiss colleagues at Roche Pharmaceuticals to create a leukemia-on-a-chip model. The challenge was to see whether it was possible to reproduce on the chip the known effects and toxicities of diclofenac and imatinib in people.
As published in Science Translational Medicine, they more than met the challenge. The researchers showed as expected that imatinib did not harm liver cells [1]. But, when treated with diclofenac, liver cells on the chip were reduced in number by about 30 percent, an observation consistent with the drug’s known liver toxicity profile.
As a second and more challenging test, the researchers reconfigured the BOC by placing a multi-drug resistant vulva cancer cell line in one chamber and, in another, a breast cancer cell line that responded to drug treatment. To explore side effects, the system also incorporated a chamber with human liver cells and two others containing beating human heart cells, along with devices to measure the cells’ electrical and mechanical activity separately.
These studies showed that tamoxifen, commonly used to treat breast cancer, indeed killed a significant number of the breast cancer cells on the BOC. But, it only did so after liver cells on the chip processed the tamoxifen to produce its more active metabolite! 
Meanwhile, tamoxifen alone didn’t affect the drug-resistant vulva cancer cells on the chip, whether or not liver cells were present. This type of cancer cell has previously been shown to pump the drug out through a specific channel. Studies on the chip showed that this form of drug resistance could be overcome by adding a second drug called verapamil, which blocks the channel.
Both tamoxifen alone and the combination treatment showed some off-target effects on heart cells. While the heart cells survived the treatment, they contracted more slowly and with less force. The encouraging news was that the heart cells bounced back from the tamoxifen-only treatment within three days. But when the drug-drug combination was tested, the cardiac cells did not recover their function during the same time period.
What makes advances like this especially important is that only 1 in 10 drug candidates entering human clinical trials ultimately receives approval from the Food and Drug Administration (FDA) [2]. Often, drug candidates fail because they prove toxic to the human brain, liver, kidneys, or other organs in ways that preclinical studies in animals didn’t predict. 
As BOCs are put to work in testing new drug candidates and especially treatment combinations, the hope is that we can do a better job of predicting early on which chemical compounds will prove safe and effective in humans. For those drug candidates that are ultimately doomed, “failing early” is key to reducing drug development costs. By culturing an individual patient’s cells in the chambers, BOCs also may be used to help doctors select the best treatment option for that particular patient. The ultimate goal is to accelerate the translation of basic discoveries into clinical breakthroughs. For more information about tissue chips, take a look at NIH’s Tissue Chip for Drug Screening program
References:
[1] Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. McAleer CW, Long CJ, Elbrecht D, Sasserath T, Bridges LR, Rumsey JW, Martin C, Schnepper M, Wang Y, Schuler F, Roth AB, Funk C, Shuler ML, Hickman JJ. Sci Transl Med. 2019 Jun 19;11(497).
[2] Clinical development success rates for investigational drugs. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Nat Biotechnol. 2014 Jan;32(1):40-51

Tuesday, September 10, 2019

13th Annual Learning for Living Symposium: September 14th, 2019 Four Seasons Hotel Ballroom – 2nd Floor 200 Boylston Street, Boston

Don't forget to signup for the 13th Annual Learning for Living for September 14, 2019. 

WHEN: September 14th, 2019

WHERE: Four Seasons Hotel Ballroom – 2nd Floor
200 Boylston Street, Boston

WHAT:

It's sponsored by Ovations for the Cure and the line up of topics will be of interest to many.

It's FREE and women are encouraged to bring a guest. Parking is at a discount and there's always a wonderful breakfast and lunch. There's a great line-up of speakers covering many topics.

Some of the topics will include the latest update on PARP inhibitors, misconceptions about clinical trials, a Q&A session and a session on hospital vs network based patient centered care for advanced ovarian cancer. To sign up, follow this link.